Strategy (MSTR) Stock Declines Despite $1 Billion Bitcoin Purchase Pushing Holdi...
Strategy (MSTR) stock declined 2.5% after purchasing 13,927 Bitcoin for $1B through STRC stock sales, bringing total holdings to 7...
Morgan Stanley Downgrades Kering (PRTP) Stock Amid Persistent Gucci Struggles
Kering (PRTP) stock dropped 3% after Morgan Stanley downgraded the luxury giant, expressing concern over Gucci's recovery pace and...
Nebius (NBIS) Stock Downgraded Despite Price Target Hike Following 70% Surge
Nebius (NBIS) downgraded to Hold by Freedom Capital despite $154 price target and strong growth outlook following 70% two-month ra...
Archer Aviation (ACHR) Stock Soars Nearly 380% — Inside the Explosive Rally
Archer Aviation (ACHR) stock surged 378% in three months. Discover how FAA endorsement and Starlink connectivity are driving the e...
JPMorgan Urges Investors to Capitalize on Market Dips Amid Global Volatility
JPMorgan recommends buying market dips, highlighting strong earnings growth, controlled inflation, and emerging markets trading at...
Somnigroup Acquires Leggett & Platt (LEG) in $2.5B All-Stock Transaction
Leggett & Platt (LEG) stock surges 5.7% as Somnigroup (SGI) confirms $2.5B all-stock takeover deal expected to close by late 2026....
T-Mobile (TMUS) Stock Climbs on KeyBanc Analyst Upgrade: 33% Gain Projected
KeyBanc upgrades T-Mobile (TMUS) to Overweight with $260 target, suggesting 33% upside potential based on compressed valuation and...
Trump Orders Naval Blockade of Strait of Hormuz: Markets Tumble as Oil Surges Pa...
Stock futures dropped and oil prices surged above $100 after Trump ordered a naval blockade of the Strait of Hormuz. Iran vows ret...
Goldman Sachs (GS) Stock Surges on Strong Q1 Results and Record Equities Trading
Goldman Sachs (GS) stock rallies after reporting Q1 earnings of $5.63B, up 19%. Record equities revenue and investment banking fee...
IDEAYA Biosciences (IDYA) Soars 26% on Breakthrough Eye Cancer Trial Data
IDEAYA Biosciences (IDYA) stock jumped 26% after its eye cancer drug combo doubled progression-free survival in a Phase 2/3 trial...